TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34852677

Group type: EXPERIMENTAL
Intervention: Immediate mobilization with a removable forearm splint for one week and active supervised group physiotherapy and home exercises from the first postoperative day.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Immediate mobilization group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cast immobilization group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Immediate mobilization group and Cast immobilization group
Number of subjects: 116
Study: 35403537

Group type: EXPERIMENTAL
Intervention: Moderate sedation
Number of subjects: 470

Group type: COMPARATOR
Intervention: Deep sedation
Number of subjects: 470
Study: 32346190

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based soap + alcohol-based chlorhexidine (CSAC)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based soap + 70% ethyl alcohol + alcohol-based chlorhexidine (CSAAC)
Number of subjects: 170
Study: 34627672

Group type: EXPERIMENTAL
Intervention: 12-week early moderate-intensity resistance training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Aerobic-based rehabilitation (control)
Number of subjects: 31
Study: 33221618

Group type: EXPERIMENTAL
Intervention: New C-arm system with improved hardware and optimized image processing algorithms
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional angiography unit B
Number of subjects: 49
Study: 32706428

Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no TRT)
Number of subjects: 60
Study: 35732555

Group type: EXPERIMENTAL
Intervention: Insomnia with short sleep duration (ISSD)
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Insomnia with normal sleep duration (INSD)
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Normal sleepers (≥6 hours)
Number of subjects: 1741
Study: 34699271

Group type: EXPERIMENTAL
Intervention: Transoral surgery (TOS) plus 50 Gy postoperative radiation therapy (RT)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Transoral surgery (TOS) plus 60 Gy postoperative radiation therapy (RT)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Transoral surgery (TOS) plus 66 Gy RT and weekly cisplatin
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Transoral surgery (TOS) with observation
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Functional assessment of cancer therapy-head and neck
Number of subjects: 495
Study: 33896813

Group type: EXPERIMENTAL
Intervention: WeChat rehabilitation guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional discharge guidance
Number of subjects: 0
Study: 35979216

Group type: EXPERIMENTAL
Intervention: Jinhua Qinggan granules (JHQG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 34349267

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin therapy (using faster insulin aspart)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard insulin therapy (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin therapy
Number of subjects: 26
Study: 32194001

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Program
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 40
Study: 34508882

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 μg daily for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study: 35155674

Group type: EXPERIMENTAL
Intervention: Group counselling with spiritual content in eight sessions at 16 to 20 weeks of gestation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group counselling with spiritual content
Number of subjects: 40
Study: 33446071

Group type: EXPERIMENTAL
Intervention: Action Video Game (AVG) training for 40 minutes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-AVG training for 40 minutes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both AVG and non-AVG groups
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Experienced AVG players
Number of subjects: 29
Study: 33109532

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP) plus existing services
Number of subjects: 739

Group type: COMPARATOR
Intervention: Existing services
Number of subjects: 739
Study: 35467938

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 149

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 149
Study: 33436700

Group type: EXPERIMENTAL
Intervention: Traction suture at the corneal limbus (CS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Superior rectus muscle suture (MS)
Number of subjects: 41
Study: 33838357

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) at a maximum dose of 0.2 micrograms per kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (control) injected 30 min before surgery
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 44
Study: 33438009

Group type: EXPERIMENTAL
Intervention: Low added sugar intake (0 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium added sugar intake (75 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High added sugar intake (150 g/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High intake at lunch and low intake at breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline fasting breath CIR
Number of subjects: 12
Study: 32360142

Group type: EXPERIMENTAL
Intervention: Aminosidine (15 mg/kg, subcutaneously, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meglumine antimoniate (100 mg/kg SC, once daily, for 28 days) and allopurinol (10 mg/kg, per os, twice daily, for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meglumine antimoniate-allopurinol combination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aminosidine-allopurinol combination
Number of subjects: 40
Study: 34906572

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 97
Study: 34763774

Group type: COMPARATOR
Intervention: 1-year DAPT
Number of subjects: 15083

Group type: EXPERIMENTAL
Intervention: ≤6-month DAPT
Number of subjects: 15083
Study: 33885035

Group type: EXPERIMENTAL
Intervention: EMLA cream (n=75)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo cream (n=77)
Number of subjects: 27
Study: 32285282

Group type: EXPERIMENTAL
Intervention: Brief educational intervention on multi-modal pain control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100
Study: 35147086

Group type: EXPERIMENTAL
Intervention: 1000 mg Liriope platyphylla extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33946101

Group type: EXPERIMENTAL
Intervention: Daily text messages sent via WhatsApp during the study period (group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No text messages received (control group, group 2)
Number of subjects: 44
Study: 32583727

Group type: EXPERIMENTAL
Intervention: Aerobic fitness test performed prior to memory test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic fitness test performed after memory test
Number of subjects: 0
Study: 35772861

Group type: EXPERIMENTAL
Intervention: atrasentan 0.75 mg/day
Number of subjects: 3668

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3668
Study: 33878853

Group type: COMPARATOR
Intervention: Poorly-controlled group (PC) - HbA1c > 7.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Well-controlled group (WC) - HbA1c ≤ 7.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Poorly-controlled group (PC)
Number of subjects: 50
Study: 35120593

Group type: EXPERIMENTAL
Intervention: Atrial shunt device
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 1072
Study: 34583306

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretations (CBM-I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Active control training
Number of subjects: 71
Study: 36054166

Group type: EXPERIMENTAL
Intervention: Topical methotrexate 1% gel (MTX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical calcipotriol 0.005% cream (CPL)
Number of subjects: 40
Study: 32512234

Group type: EXPERIMENTAL
Intervention: O2‐Suppl (100%)
Number of subjects: 11
Study: 32536213

Group type: EXPERIMENTAL
Intervention: FLASH sexual health education curriculum
Number of subjects: 222
Study: 32080218

Group type: EXPERIMENTAL
Intervention: GumChucks
Number of subjects: 40

Group type: COMPARATOR
Intervention: String Floss (SF)
Number of subjects: 40
Study: 34600798

Group type: EXPERIMENTAL
Intervention: Interventional group (surgical intervention triggered by CM drop)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with no CM drop during insertion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with recovered CM after initial drop
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with CM drop during insertion
Number of subjects: 60
Study: 34535158

Group type: EXPERIMENTAL
Intervention: Early awake prone positioning (APP) initiated within 24 hours of high-flow nasal cannula (HFNC) start
Number of subjects: 125

Group type: COMPARATOR
Intervention: Late awake prone positioning (APP) initiated after 24 hours of high-flow nasal cannula (HFNC) start
Number of subjects: 125
Study: 32938723

Group type: EXPERIMENTAL
Intervention: Radical surgery including pelvic and para-aortic lymphadenectomy and subsequent platinum-based chemotherapy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Sexually active patients
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Sexually inactive patients
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Overall patient responses
Number of subjects: 495
Study: 34110455

Group type: EXPERIMENTAL
Intervention: Anteriorly pedicled osteoplastic flap for mastoid closure (Case group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Traditional periosteal flap (Control group)
Number of subjects: 126
Study: 33217063

Group type: EXPERIMENTAL
Intervention: Allergic asthma
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: Eosinophilic asthma
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: Type 2 asthma
Number of subjects: 1984
Study: 33372122

Group type: EXPERIMENTAL
Intervention: SBIRT
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 289
Study: 32817407

Group type: EXPERIMENTAL
Intervention: PIB with 0.2% ropivacaine (group 2, n=27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PIB with saline infusion (group 1, n=23)
Number of subjects: 50
Study: 35391838

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 192
Study: 35178371

Group type: EXPERIMENTAL
Intervention: Faith-Based Interventions (FBIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social support and religiosity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Types of FBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 33064413

Group type: EXPERIMENTAL
Intervention: N + C supplementation (520 mg nitrate and 6 g citrulline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 616191460

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) given prophylactically at 20-50% of daily dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36189733

Group type: EXPERIMENTAL
Intervention: Preoperative adductor canal block (ACB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Postoperative adductor canal block (ACB)
Number of subjects: 50
Study: 33368570

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sham cryotherapy
Number of subjects: 172
Study: 32480361

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (HBR) system using smartwatch and smartphone app
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 23
Study: 36150070

Group type: EXPERIMENTAL
Intervention: Screened for STI during pregnancy (n=3483)
Number of subjects: 4553

Group type: EXPERIMENTAL
Intervention: Predictors of positive STI test
Number of subjects: 4553
Study: 33961343

Group type: EXPERIMENTAL
Intervention: Elastic Stable Intramedullary Nailing (ESIN)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Metal Plate Internal Fixation (MPIF)
Number of subjects: 350
Study: 32113613

Group type: EXPERIMENTAL
Intervention: Music tuned to 440 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Music tuned to 432 Hz
Number of subjects: 0
Study: 35779695

Group type: EXPERIMENTAL
Intervention: Test I (additional 40 minutes of outdoor time)
Number of subjects: 6295

Group type: EXPERIMENTAL
Intervention: Test II (additional 80 minutes of outdoor time)
Number of subjects: 6295

Group type: COMPARATOR
Intervention: Control (habitual outdoor time)
Number of subjects: 6295
Study: 33637220

Group type: COMPARATOR
Intervention: Conventional amplification strategy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Notch filter amplification strategy
Number of subjects: 39
Study: 33235439

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV)
Number of subjects: 276

Group type: COMPARATOR
Intervention: 5 mg nebivolol (NEBI)
Number of subjects: 276

Group type: COMPARATOR
Intervention: 20 mg rosuvastatin (RSV)
Number of subjects: 276
Study: 35090411

Group type: EXPERIMENTAL
Intervention: VIPP-PUF intervention
Number of subjects: 900
Study: 32539663

Group type: EXPERIMENTAL
Intervention: 2 mg/kg weight-based dosing (to a maximum of 200 mg)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Flat dosing of 200 mg
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Vial sharing using 100 mg vials
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Vial sharing practices
Number of subjects: 384
Study: 36424267

Group type: EXPERIMENTAL
Intervention: FEMT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: WAMT
Number of subjects: 35
Study: 34697965

Group type: EXPERIMENTAL
Intervention: d-amphetamine (30 mg BID) during week 1, switched to placebo during weeks 2-3, placebo during week 4
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo during weeks 2-3 and week 4
Number of subjects: 34
Study: 35137696

Group type: EXPERIMENTAL
Intervention: ClearVisc
Number of subjects: 372

Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 372
Study: 36309966

Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline (10–20 mg based on self‐titration)
Number of subjects: 752
Study: 32282044

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (ENABLE CHF-PC) consisting of four weekly psychosocial and problem-solving support telephonic sessions lasting 20-60 minutes facilitated by a trained nurse coach plus monthly follow-up for 48 weeks.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (no additional intervention)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (ENABLE CHF-PC)
Number of subjects: 158
Study: 35908130

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR), n = 25
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control, n = 28
Number of subjects: 58
Study: 34979571

Group type: EXPERIMENTAL
Intervention: Monthly video consultations plus regular care (IG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Regular care only (WG)
Number of subjects: 240
Study: 34747448

Group type: EXPERIMENTAL
Intervention: Ansofaxine 40 mg/d
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ansofaxine 80 mg/d
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ansofaxine 120 mg/d
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ansofaxine 160 mg/d
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 35372992

Group type: EXPERIMENTAL
Intervention: High-dose IV iron administered proactively
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Low-dose IV iron administered reactively
Number of subjects: 2141
Study: 36101805

Group type: EXPERIMENTAL
Intervention: Qinfan decoction combined with VSD
Number of subjects: 69

Group type: COMPARATOR
Intervention: VSD
Number of subjects: 69
Study: 35363812

Group type: EXPERIMENTAL
Intervention: Fatigue Group (shoulder fatigue protocol with dominant arm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (10-minute break)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fatigue Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study: 34184057

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 32021087

Group type: EXPERIMENTAL
Intervention: 3 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 9 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 ng/kg/min AM via continuous 12-h intravenous infusion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 ng/kg/min AM for 8 h per day for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34617277

Group type: EXPERIMENTAL
Intervention: Ketoprofen (3 mg/kg, Ketofen 10%, Ceva Animal Health)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (topical application of oxytetracycline spray only)
Number of subjects: 158
Study: 32345356

Group type: EXPERIMENTAL
Intervention: Copeptin measured at 24 hours
Number of subjects: 690
Study: 35780725

Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus methylprednisolone
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Zoledronic acid alone
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Zoledronic acid with or without methylprednisolone
Number of subjects: 262
Study: 32938325

Group type: EXPERIMENTAL
Intervention: Stabilization Group (SG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Superstabilization Group (SSG)
Number of subjects: 40
Study: 33724373

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control arm (tenofovir disoproxil fumarate/emtricitabine with a third agent)
Number of subjects: 223
Study: 33261981

Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) adenoid ablation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Curettage group
Number of subjects: 80
Study: 32080085

Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage (ENGBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transhepatic gallbladder drainage (PTGBD)
Number of subjects: 0
Study: 35238406

Group type: EXPERIMENTAL
Intervention: Deception group (consultant as a subject)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-deception group (consultant acting a part)
Number of subjects: 44
Study: 35135967

Group type: EXPERIMENTAL
Intervention: CytoSorb for 3-7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 50
Study: 33711221

Group type: EXPERIMENTAL
Intervention: Body fat percent increase
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Trunk fat percent increase
Number of subjects: 2160
Study: 32239210

Group type: EXPERIMENTAL
Intervention: Delayed TARGIT‐IORT
Number of subjects: 1153

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 1153
Study: 35922124

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg two times per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 0
Study: 33249580

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB) 120 mg
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB) 240 mg
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB)
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2886
Study: 35508860

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention at bilateral Zusanli (ST 36), Shangjuxu (ST 37), Xiajuxu (ST 39), Tianshu (ST 25), and Zhongwan (RN 12) acupoints, 30 min per time, twice daily, for 7 days
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention
Number of subjects: 500
Study: 33455137

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (monosialotetrahexose ganglioside sodium + conventional rehabilitation)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Conventional treatment group (conventional rehabilitation)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 144
Study: 32045314

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 0
Study: 34051142

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 208

Group type: COMPARATOR
Intervention: Benzylpenicillin
Number of subjects: 208
Study: 33020204

Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose of 400 mg/m2 IV followed by weekly doses of 250 mg/m2, one cycle = 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 30
Study: 34647301

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 386
Study: 33464580

Group type: EXPERIMENTAL
Intervention: Besa 2.0
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Encevis 1.7
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Persyst 13
Number of subjects: 81
Study: 34571095

Group type: EXPERIMENTAL
Intervention: Lesogaberan (120 mg MR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15